Table 2.
Detailed patient characteristics and outcome
| P# | Age and Gender at Infusion | Stage at Diagnosis | Prior Therapy | Site of Disease at Infusion | CTL* (Dose Level) | Response to Therapy (Duration in Months) | ||
|---|---|---|---|---|---|---|---|---|
| CT | XRT | |||||||
| 729 | 50 | F | IV: T4N3bM0 | 1 | 1 | NED | 2 (1) | Remains in remission (>82 mths); alive |
| 606 | 59 | F | III: T3N2M0 | 1 | 1 | NED | 2 (1) | Recurrent disease (60 mths); alive |
| 697 | 11 | F | III: T1N2M0 | 1 | 1 | NED | 2 (1) | Remains in remission (>80 mths); alive |
| 1642 | 11 | M | IV: TXNXM1 | 3 | 1 | NED | 2 (3) | Remains in remission (>42 mths); alive |
| 1946 | 63 | F | III: T3N1M0 | 1 | 1 | NED | 2 (3) | Remains in remission (>28 mths); alive |
| 1969 | 38 | M | III: T3N0M0 | 2 | 2 | NED | 2 (3) | Recurrent disease (14 mths); died at 27 mths |
| 2024 | 60 | M | III: T2N2M0 | 1 | 1 | NED | 2 (3) | Recurrent disease (2 mths); alive |
| 2047 | 16 | M | II: T2N1M0 | 3 | 3 | NED | 2 (3) | Remains in remission (>25 mths); alive |
| 894 | 36 | M | III: T3N0M0 | 3 | 2 | Primary site | 2 (2) | CR (44 mths); died at 65 mths |
| 389 | 17 | F | IV: T4N2M0 | 2 | 1 | Primary site | 5 (2) | CR (>53 mths); alive |
| 918 | 16 | M | IV: T4N2M0 | 1 | 1 | Primary site | 2 (2) | PR (12 mths); died at 20 mths |
| 815 | 19 | M | IV: T4N3M0 | 1 | 1 | Primary site (unknown significance) | 2 (3) | CRu (>46 mths); alive |
| 845 | 11 | M | IV: T4N2M0 | 6 | 2 | Primary site, LN | 1 (1) | PD; died at 12 mths |
| 1042 | 46 | F | II: T2N1M0 | 2 | 2 | Bone | 2 (3) | CR (>68mths); alive |
| 1046 | 16 | M | IV: T2bN3M0 | 4 | 1 | LN, bone | 2 (3) | SD (2 mths); died at 3 mths |
| 1241 | 18 | M | IV: T4N1M0 | 3 | 2 | Lung (unknown significance) | 2 (3) | CRu (36 mths); alive |
| 1902 | 17 | M | III: T3N1M0 | 2 | 1 | Primary site, bone, lung | 2 (3) | PD; died at 14 mths |
| 1968 | 34 | M | IV: T4N1M0 | 4 | 2 | Primary site, lung, CNS | 2 (3) | PD; died at 11 mths |
| 2019 | 17 | M | IV: T4N3M0 | 3 | 3 | Primary site, bone | 2 (3) | SD (4 mths); died at 7 mths |
| 2061 | 32 | M | IV: T0N3M1 | 4 | 1 | Primary, LN, bone, lung | 2 (3) | PD; died at 16 mths |
| 2078 | 16 | M | IV: T2N3aM1 | 4 | 2 | LN, bone, soft tissue | 2 (3) | PD; died at 7 mths |
| 1668 | 21 | M | IV: T4N2aM0 | 4 | 4 | LN, bone | 3 (3) | PR (7 mths); alive |
| 1976 | 48 | M | I: T1N0M0 | 3 | 1 | Lung | 6 (3) | SD (12 mths); alive |
P#: patient identification number; CT: chemotherapy regimens; XRT: radiotherapy regimens; NED: no evidence of disease; LN: lymph node; CNS: central nervous system; CTL*: number of CTL infusions; Mths: months; CR: complete response; PR: partial response; CRu: complete response undetermined; SD: stable disease; PD: progressive disease